BTBP(SH:600161) Zheng Quan Zhi Xing·2025-08-21 10:07Core Viewpoint - Beijing Tiantan Biological Products Co., Ltd. reported a decrease in net profit and cash flow for the first half of 2025, despite an increase in revenue, indicating potential challenges in operational efficiency and profitability [1][3]. Financial Summary - Total assets at the end of the reporting period reached CNY 16.52 billion, a 4.11% increase from the previous year [1]. - Net assets attributable to shareholders increased by 3.90% to CNY 11.57 billion [1]. - Revenue for the period was CNY 3.11 billion, reflecting a 9.47% increase year-on-year [1]. - Total profit decreased by 12.77% to CNY 1.04 billion [1]. - Net profit attributable to shareholders fell by 12.88% to CNY 632.56 million [1]. - The net cash flow from operating activities was negative at CNY -201.90 million, a significant decline of 116.73% compared to the previous year [1]. - The weighted average return on net assets decreased by 1.62 percentage points to 5.54% [1]. Dividend Distribution - The company plans to distribute a cash dividend of CNY 1.5 per 10 shares, totaling CNY 296.61 million, based on a total share capital of 1,977,371,446 shares as of June 30, 2025 [1]. Shareholder Information - The largest shareholder, China National Biotechnology Group Corporation, holds 45.64% of the shares [2]. - Other significant shareholders include Chengdu Biological Products Research Institute and various investment funds, with the top ten shareholders holding a diverse range of stakes [2]. Important Matters - The report indicates that there were no significant changes in the company's operational situation or any major events that would impact future operations during the reporting period [3].